Antifungal therapy in the ITU/HDU setting in the Czech Republic: Prospective, observational study
Authors:
V. Černý 1,2,3,4; N. Mallátová 5; M. Matějovič 6; I. Novák 6; P. Sklienka 7; Za Pracovní Skupinu Studie (viz Seznam Na Konci 8
Authors‘ workplace:
Klinika anesteziologie, perioperační a intenzivní medicíny, Univerzita J. E. Purkyně v Ústí nad Labem, Masarykova nemocnice v Ústí nad Labem, Institut postgraduálního vzdělávání ve zdravotnictví Praha
1; Centrum pro výzkum a vývoj, Fakultní nemocnice Hradec Králové
2; Dept. of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada
3; Klinika anesteziologie, resuscitace a intenzivní medicíny, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové
4; Pracoviště parazitologie a mykologie, Centrální laboratoře, Nemocnice České Budějovice, a. s.
5; I. interní klinika a Biomedicínské centrum, Univerzita Karlova v Praze, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň
6; Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Ostrava. Lékařská fakulta Ostravské Univerzity, Ostrava
7; Katedra intenzivní medicíny a forenzních oborů, Lékařská fakulta Ostravské Univerzity, Ostrava
8
Published in:
Anest. intenziv. Med., 27, 2016, č. 3, s. 142-148
Category:
Intensive Care Medicine - Original Paper
Overview
This prospective, questionnaire, observational study collected data on 123 patients in whom antifungal therapy was commenced during the observed month. Total 116 patients from 23 Czech Republic ITU/HDUs were included in the analysis. The most frequent indication for antifungal therapy was pre-emptive treatment (73 patients). Targeted antifungal therapy was used in 20 patients. The most commonly cited reasons for commencing antifungal therapy were urinary catheter, central venous catheter, invasive airway management, total parenteral nutrition, mechanical ventilation and broad-spectrum antibiotic therapy. The most frequently used initial antifungal agent was intravenous fluconazole and the most commonly isolated fungal organism was Candida albicans. Mortality of antifungal-treated patients in the observed period reached 25%. Our outcomes mostly match the outcomes of similar studies performed abroad.
KEYWORDS:
fungi – intensive care – therapy
Sources
1. Aubron, C., Suzuki, S., Glassford, N. J. et al. The epidemiology of bacteriuria and candiduria in critically ill patients. Epidemiol. Infect., 2015,143, 3, p. 653–662.
2. Bassetti, M., Merelli, M., Righi, E. et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J. Clin. Microbiol., 2013, 51, 12, p. 4167–4172.
3. Blot, S., Charles, P. E. Fungal sepsis in the ICU: are we doing better? Trends in incidence, diagnosis, and outcome. Minerva Anestesiol., 2013, 79, 12, p. 1396–1405.
4. Pratikaki, M., Platsouka, E., Sotiropoulou, C. et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses, 2011, 54, 2, p. 154–161.
5. Weiss, E., Timsit, J. F. Management of invasive candidiasis in nonneutropenic ICU patients. Ther. Adv. Infect. Dis., 2014, 2, 5–6, p. 105–115.
6. León, C., Ostrosky-Zeichner, L., Schuster, M. What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med., 2014, 40, 6, p. 808–819.
7. Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin. Microbiol. Infect., 2014, 20, Suppl 6, p. 5–10.
8. Muskett, H., Shahin, J., Eyres, G. et al. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit. Care, 2011, 15, 6, p. R287.
9. Paiva, J. A., Pereira, J. M. Fluoroquinolones: another line in the long list of their collateral damage record. Crit. Care Med., 2015, 43, 3, p. 708–710.
10. Eloy, O., Blanc, V., Pina, P. et al. Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004. Pathol. Biol., 54, 8–9, p. 523–530.
11. Kett, D. H., Azoulay, E., Echeverria, P. M., Vincent, J. L. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med., 2011, 39, 4, p. 665–670.
12. Tortorano, A. M., Dho, G., Prigitano, A. et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008). Mycoses, 2012, 55, 1, p. 73–79.
13. Vincent, J. L., Bihari, D. J., Suter, P. M. et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA, 274, 8, p. 639–644.
14. Pauw, B. De, Walsh, T. J., Donnelly, J. P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin. Infect. Dis., 2008, 46, 12, p. 1813–1821.
15. Drgona, L., Khachatryan, A., Stephens, J. et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis., 2014, 33, 1, p. 7–21.
16. Ferreira, D., Grenouillet, F., Blasco, G. et al. Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive Care Med., 2015, 41, 6, p. 1077–1088.
17. Lau, A. F., Kabir, M., Chen, S. C. A. et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. J. Clin. Microbiol., 2015, 53, 4, p. 1324–1330.
18. Pittet, D., Monod, M., Suter, P. M., Frenk, E., Auckenthaler, R. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg., 1994, 220, 6, p. 751–758.
19. Charles, P. E., Dalle, F., Aube, H. et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med., 2005, 31, 3, p. 393–400.
20. Bassetti, M., Righi, E., Ansaldi, F. et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med., 2014, 40, 6, p. 839–845.
21. Kollef, M., Micek, S., Hampton, N., Doherty, J. A., Kumar, A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin. Infect. Dis., 2012, 54, 12, p. 1739–1746.
22. Grim, S. A., Berger, K., Teng, C. et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J. Antimicrob. Chemother., 2012, 67, 3, p. 707–714.
23. Kratzer, C., Graninger, W., Lassnigg, A., Presterl, E. Design and use of Candida scores at the intensive care unit. Mycoses, 2011, 54, 6, p. 467–474.
24. Leroy, G., Lambiotte, F., Thévenin, D. et al. Evaluation of “Candida score” in critically ill patients: a prospective, multicenter, observational, cohort study. Ann. Intensive Care, 2011, 1, 1, p. 50.
25. Tapia, G. G., Razonable, R. R., Eckel-Passow, J. E. et al. A scoring model of factors associated with Candida glabrata candidemia among critically ill patients. Mycoses, 2012, 55, 3, p. 228–236.
26. Harrison, D., Muskett, H., Harvey, S. et al. Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study. Health Technol. Assess, 2013, 17, 3, p. 1–156.
27. Cornely, O. A., Bassetti, M., Calandra, T. et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect., 2012, 18, Suppl 7, p. 19–37.
28. Gaspar, G. G., Menegueti, M. G., Auxiliadora-Martins, M., Basile-Filho, A., Martinez, R. Evaluation of the predictive indices for candidemia in an adult intensive care unit. Rev. Soc. Bras. Med. Trop., 48, 1, p. 77–82.
29. Colombo, A. L., Guimarães, T., Sukienik, T. et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med., 2014, 40, 10, p. 1489–1498.
30. Bailly, S., Bouadma, L., Azoulay, E. et al. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients. Am. J. Respir. Crit. Care Med., 2015, 191, 10, p. 1139–1146.
31. Azoulay, E., Dupont, H., Tabah, A. et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit. Care Med., 2012, 40, 3, p. 813–822.
32. Chen, S. C., Sorrell, T. C., Chang, C. C. et al. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern. Med. J., 2014, 44, 12b, p. 1315–1332.
33. Lortholary, O., Renaudat, C., Sitbon, K. et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med., 2014, 40, 9, p. 1303–1312.
34. Pappas, P. G., Kauffman, C. A., Andes, D. R. et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis., 2015.
35. Hsu, J. L., Ruoss, S. J., Bower, N. D. et al. Diagnosing invasive fungal disease in critically ill patients. Crit. Rev. Microbiol., 2011, 37, 4, p. 277–312.
36. Aguilar, G., Delgado, C., Corrales, I. et al. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study. BMC Res. Notes., 2015, 8, p. 491.
37. Montagna, M. T., Caggiano, G., Lovero, G. et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection, 2013, 41, 3, p. 645–653.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2016 Issue 3
Most read in this issue
- Pleural effusion in intensive care
- Tracheal damage as a consequence of percutaneous dilatation tracheostomy – case reports and review of literature
- Echocardiographic examination in mitral valve disease
- The role of simulation in the evolution of anaesthesia and intensive care medicine